Related Experiment Videos

Introduction: the dual-action debate: does pharmacology matter?

Michael E Thase¹

¹Department of Psychiatry, University of Pittsburgh Medical Center, 3811 O'Hara St., Pittsburgh, PA 15213-2593, USA. thaseme@upmc.edu

The Journal of Clinical Psychiatry

|December 17, 2004

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies.

Expert opinion on pharmacotherapy·2019

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2019

The Role of Dyadic Discord in Outcomes in Acute Phase Cognitive Therapy for Adults With Recurrent Major Depressive Disorder.

Behavior therapy·2019

Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?

Behavior therapy·2019

Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials.

Acta neuropsychiatrica·2019

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA psychiatry·2019

See all related articles